Quantcast
Home > Quotes > CTIC
CTIC

CTI BioPharma Corp. (DE) Common Stock (CTIC) Quote & Summary Data

$0.8255
*  
0.0205
2.55%
Get CTIC Alerts
*Delayed - data as of Jul. 16, 2019  -  Find a broker to begin trading CTIC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CTIC Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
4
Today's High / Low
$ 0.8393 / $ 0.805
Share Volume
65,421
50 Day Avg. Daily Volume
297,703
Previous Close
$ 0.805
52 Week High / Low
$ 4.17 / $ 0.6001
Market Cap
47,861,437
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.5

Intraday Chart

Shares Traded

Share Volume:
65,421
50 Day Avg. Daily Volume:
297,703

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -0.64

Trading Range

The current last sale of $0.8255 is 37.56% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.8393 $ 4.17
 Low: $ 0.805 $ 0.6001

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need and are primarily focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. Pacritinib Our primary development candidate, pacritinib, is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses.  ... More ...  



Risk Grade

Where does CTIC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.819
Open Date:
Jul. 16, 2019
Close Price:
$ 0.8255
Close Date:
Jul. 16, 2019


Consensus Recommendation

Analyst Info